Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
– Oral insulin FDA End-of-Phase 2 meeting expected this quarter – Strong balance sheet with roughly $50M in cash – NASH intermediate study data expected this quarter NEW YORK, April 1, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is […]
